The monoclonal antibody treatment reduced the risk of developing symptomatic Covid-19 by a statistically insignificant 33% among unvaccinated adults.
AstraZeneca on Tuesday announced its monoclonal antibody treatment for Covid-19 did not meet the primary goal of preventing symptoms in people who have been exposed to the coronavirus, denting hopes of a new therapeutic treatment for Covid-19 for unvaccinated people....
The antibody therapy, however, was 92% effective in preventing symptomatic Covid-19 compared to the placebo in patients who tested negative after exposure, suggesting that the drug may be effective in preventing symptoms in people who are not already infected. The drug continues to be tested as possible prophylaxis against Covid-19 in other trials, the company noted.The trial’s principal investigator, Dr. Myron J.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Kate Middleton says COVID-19 changed her perspective on familyThe pandemic caused the duchess to reflect on family bonds
Read more »
Positive Covid-19 Tests Fall to Lowest Recorded RateSome 2% of Covid-19 tests in the U.S. are coming back positive, the lowest positivity rate since the pandemic took hold in the country
Read more »
Covid-19: NI records 70 new cases and no further deathsNo new coronavirus-linked deaths were reported on Sunday, which keeps the total at 2,155.
Read more »
What to Know About Vitamin D and COVID-19One study found that high levels of vitamin D might lower your risk for severe COVID-19 infection, but how much can it help? What we know so far:
Read more »
California lista para cancelar decenas de acciones de emergencia contra el COVID-19California se moviliza para anular docenas de acciones de emergencia COVID-19 a medida que se acerca la reapertura
Read more »
Pompeo insists Covid-19 leaked from a Chinese labFormer Secretary of State Mike Pompeo insisted on Sunday that Covid-19 originated from a Chinese lab, but he offered no specifics
Read more »